Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 15/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1169690 | 0.90 | CXCR3 (0.81) | CXCR3KCNA5KMT2APDE4APDE4B | |
| SCHEMBL1169573 | 0.87 | CXCR3 (1.00) | CXCR3KCNA5KMT2ATAS2R14PDE4A | |
| SCHEMBL1169514 | 0.87 | CXCR3 (0.76) | CXCR3KCNA5KMT2ATAS2R14PDE4A | |
| SCHEMBL1169383 | 0.84 | CXCR3 (0.78) | CXCR3KCNA5KMT2ATAS2R14MEN1 | |
| SCHEMBL13649445 | 0.84 | CXCR3 (0.72) | CXCR3KCNA5KMT2APDE4APDE4B | |
| SCHEMBL1170074 | 0.83 | CXCR3 (1.00) | CXCR3KMT2ATAS2R14MEN1 | |
| SCHEMBL1169828 | 0.83 | CXCR3 (0.71) | CXCR3KCNA5KMT2APDE4APDE4B | |
| SCHEMBL1287453 | 0.81 | CXCR3 (0.72) | CXCR3KMT2ATAS2R14MEN1 | |
| SCHEMBL12863149 | 0.79 | CXCR3 (0.72) | CXCR3KCNA5KMT2A | |
| SCHEMBL3436412 | 0.79 | CXCR3 (0.72) | CXCR3KCNA5KMT2ATAS2R14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2009124962-A2 | SULFONAMIDES | MERCK SERONO S.A. (CH) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028509-A1 | Sulfonamides | CXCR3, CXCR2, CXCR1 | CXCR3 1/4885KCNA5 1177/4885KMT2A 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.